Articles written by Samuel Demaria Jr.
One Institution’s Response to the Perioperative Risk of GLP-1 Receptor Agonists
Since approval of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes mellitus, these drugs have become widely prescribed for the specific purpose of weight loss. A recent study estimated that 2% of all adult residents in the area surrounding Mount Sinai Hospital were prescribed one of these agents.
Read the articlePerioperative Management of GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus, but they have recently emerged as a common (and even fashionable) drug for weight loss.
Read the article



